A Observational Study to Evaluate Deucravacitinib in Patients With Moderate Plaque Psoriasis in China

NCT06512337 · tracked via the Priya Life Science China tracker

Sponsor

Bristol-Myers Squibb

Phase

Observational

Started

2025-01-20

Last updated

2026-04-15

Condition(s) studied

Plaque Psoriasis

Investigational drug(s) / intervention(s)

Deucravacitinib

Deucravacitinib: As per product label

Study summary

The purpose of this study is to collect and evaluate real-world data on the effectiveness of deucravacitinib treatment in adults with moderate plaque psoriasis in China.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * Participant aged 18 years or older * Physician-reported (dermatologist) diagnosis of moderate plaque psoriasis with Body Surface Area ≥ 3% and \< 10% * Participant newly initiated deucravacitinib according to the label * Provided written informed consent to participate in the study Exclusion Criteria: * Participating in or planning to participate in an interventional clinical trial * Concomitant use of other systemic treatments for psoriasis at baseline * Prior treatment of deucravacitinib

Primary outcome measure(s)

Number of participants achieving Static Physician's Global Assessment (sPGA) 0/1 score — Week 16
Participant psoriasis Body Surface Area (BSA) involvement — Week 16
Number of participants achieving absolute Psoriasis Area and Severity Index (PASI) score ≤ 3 — Week 16

Trial sites (5)

Facility	City	Region
Local Institution - 0001	Guangzhou	Guangdong
Local Institution - 0002	Handan	Hebei
Local Institution - 0005	Dalian	Liaoning
Local Institution - 0004	Shanghai	Shanghai Municipality
Local Institution - 0003	Beijing	China

More Bristol-Myers Squibb trials in China

A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Recruiting

Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01) Recruiting

A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjögren's Syndrome Active, not recruiting

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BMS-986489 in Chinese Participants With Relapsed/Refractory Small Cell Lung Cancer Active, not recruiting

A Study to Determine the Efficacy and Safety of Luspatercept in Adult Participants and to Evaluate the Safety and Pharmacokinetics in and Adolescent Participants With Alpha (α)-Thalassemia Active, not recruiting

Other trials for the same condition

A Study to Evaluate the Efficacy and Safety of CS32582 in Participants With Moderate to Severe Plaque Psoriasis Recruiting

Evaluate the Efficacy and Safety of D-2570 in Subjects With Moderate to Severe Plaque Psoriasis Recruiting

A Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque Psoriasis Active, not recruiting

Efficacy and Safety of ICP-332 Versus Placebo in Participants With Moderate to Severe Plaque Psoriasis Recruiting

To Explore the Influencing Factors and Solutions for Patients With Plaque Psoriasis Undergoing Relapse Active, not recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06512337 on ClinicalTrials.gov ↗ ← All trials in China